Jeff Fairman, VP, Research at Vaxcyte, Inc. (PCVX), sold 8,060 shares at $23.73 ($192K) on 2021-02-26, disclosed to the SEC on 2021-03-02.
Open-market sale of $192k PCVX by VP, Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.73 | 3,310 | $79K | 40.9% |
| 2 | $23.73 | 3,310 | $79K | 40.9% |
| 3 | $24.34 | 1,372 | $33K | 17.4% |
| 4 | $25.33 | 68 | $2K | 0.9% |
| Total | $23.85 avg | 8,060 | $192K | 100% |
| Filing → |
| PCVX | SELL | 2022-09-07 | $257K | — | Filing → |
| PCVX | SELL | 2022-08-05 | $384K | — | Filing → |
| PCVX | SELL | 2022-05-24 | $105K | — | Filing → |